214 related articles for article (PubMed ID: 8725851)
1. Does suppression of postprandial blood glucose excursions by the alpha-glucosidase inhibitor miglitol improve insulin sensitivity in diet-treated type II diabetic patients?
Johnson AB; Taylor R
Diabetes Care; 1996 Jun; 19(6):559-63. PubMed ID: 8725851
[TBL] [Abstract][Full Text] [Related]
2. The efficacy and safety of miglitol therapy compared with glibenclamide in patients with NIDDM inadequately controlled by diet alone.
Segal P; Feig PU; Schernthaner G; Ratzmann KP; Rybka J; Petzinna D; Berlin C
Diabetes Care; 1997 May; 20(5):687-91. PubMed ID: 9135927
[TBL] [Abstract][Full Text] [Related]
3. Chronic treatment of African-American type 2 diabetic patients with alpha-glucosidase inhibition.
Johnston PS; Feig PU; Coniff RF; Krol A; Kelley DE; Mooradian AD
Diabetes Care; 1998 Mar; 21(3):416-22. PubMed ID: 9540025
[TBL] [Abstract][Full Text] [Related]
4. Long-term titrated-dose alpha-glucosidase inhibition in non-insulin-requiring Hispanic NIDDM patients.
Johnston PS; Feig PU; Coniff RF; Krol A; Davidson JA; Haffner SM
Diabetes Care; 1998 Mar; 21(3):409-15. PubMed ID: 9540024
[TBL] [Abstract][Full Text] [Related]
5. Advantages of alpha-glucosidase inhibition as monotherapy in elderly type 2 diabetic patients.
Johnston PS; Lebovitz HE; Coniff RF; Simonson DC; Raskin P; Munera CL
J Clin Endocrinol Metab; 1998 May; 83(5):1515-22. PubMed ID: 9589648
[TBL] [Abstract][Full Text] [Related]
6. Effects of 8-wk alpha-glucosidase inhibition on metabolic control, C-peptide secretion, hepatic glucose output, and peripheral insulin sensitivity in poorly controlled type II diabetic patients.
Schnack C; Prager RJ; Winkler J; Klauser RM; Schneider BG; Schernthaner G
Diabetes Care; 1989 Sep; 12(8):537-43. PubMed ID: 2673693
[TBL] [Abstract][Full Text] [Related]
7. Comparison of miglitol and glibenclamide in diet-treated type 2 diabetic patients.
Pagano G; Marena S; Corgiat-Mansin L; Cravero F; Giorda C; Bozza M; Rossi CM
Diabete Metab; 1995 Jun; 21(3):162-7. PubMed ID: 7556806
[TBL] [Abstract][Full Text] [Related]
8. Dose-dependent efficacy of miglitol, an alpha-glucosidase inhibitor, in type 2 diabetic patients on diet alone: results of a 24-week double-blind placebo-controlled study.
Drent ML; Tollefsen AT; van Heusden FH; Hoenderdos EB; Jonker JJ; van der Veen EA
Diabetes Nutr Metab; 2002 Jun; 15(3):152-9. PubMed ID: 12173729
[TBL] [Abstract][Full Text] [Related]
9. Long-term effectiveness of a new alpha-glucosidase inhibitor (BAY m1099-miglitol) in insulin-treated type 2 diabetes mellitus.
Mitrakou A; Tountas N; Raptis AE; Bauer RJ; Schulz H; Raptis SA
Diabet Med; 1998 Aug; 15(8):657-60. PubMed ID: 9702468
[TBL] [Abstract][Full Text] [Related]
10. Reduction of postprandial blood glucose by the alpha-glucosidase inhibitor Miglitol (BAY m 1099) in type II diabetes.
Heinz G; Komjati M; Korn A; Waldhäusl W
Eur J Clin Pharmacol; 1989; 37(1):33-6. PubMed ID: 2687007
[TBL] [Abstract][Full Text] [Related]
11. Post-prandial glycaemic reduction by an alpha-glucosidase inhibitor in type 2 diabetic patients with therapeutically attained basal normoglycaemia.
Holman RR; Steemson J; Turner RC
Diabetes Res; 1991 Dec; 18(4):149-53. PubMed ID: 1842749
[TBL] [Abstract][Full Text] [Related]
12. Alpha glucosidase inhibition in the treatment of non-insulin-dependent diabetes mellitus.
Scott AR; Tattersall RB
Diabet Med; 1988 Jan; 5(1):42-6. PubMed ID: 2964327
[TBL] [Abstract][Full Text] [Related]
13. alpha-Glucosidase inhibition by miglitol in NIDDM patients.
Kingma PJ; Menheere PP; Sels JP; Nieuwenhuijzen Kruseman AC
Diabetes Care; 1992 Apr; 15(4):478-83. PubMed ID: 1499461
[TBL] [Abstract][Full Text] [Related]
14. Effect of alpha-glucosidase inhibition on glucose profiles in insulin dependent diabetes.
Hillman RJ; Scott M; Gray RS
Diabetes Res; 1989 Feb; 10(2):81-4. PubMed ID: 2663321
[TBL] [Abstract][Full Text] [Related]
15. Miglitol combined with metformin improves glycaemic control in type 2 diabetes.
Van Gaal L; Maislos M; Schernthaner G; Rybka J; Segal P
Diabetes Obes Metab; 2001 Oct; 3(5):326-31. PubMed ID: 11703422
[TBL] [Abstract][Full Text] [Related]
16. Effects of alpha-glucosidase inhibition and viscous fibre on diabetic control and postprandial gut hormone responses.
Requejo F; Uttenthal LO; Bloom SR
Diabet Med; 1990 Jul; 7(6):515-20. PubMed ID: 2163805
[TBL] [Abstract][Full Text] [Related]
17. Effects of the carbohydrase inhibitor miglitol in sulfonylurea-treated NIDDM patients.
Johnston PS; Coniff RF; Hoogwerf BJ; Santiago JV; Pi-Sunyer FX; Krol A
Diabetes Care; 1994 Jan; 17(1):20-9. PubMed ID: 8112185
[TBL] [Abstract][Full Text] [Related]
18. [Delayed absorption of carbohydrates in the therapy of Type II diabetes: comparison between dietary (Muesli) and pharmacological (Alpha-glucosidase inhibition) modification].
Willms B; Lübke D; Ahrens K; Arends J
Schweiz Med Wochenschr; 1991 Sep; 121(38):1379-82. PubMed ID: 1656521
[TBL] [Abstract][Full Text] [Related]
19. Effects of BAYm 1099, new alpha-glucosidase inhibitor, on acute metabolic responses and metabolic control in NIDDM over 1 mo.
Samad AH; Ty Willing TS; Alberti KG; Taylor R
Diabetes Care; 1988 Apr; 11(4):337-44. PubMed ID: 3042310
[TBL] [Abstract][Full Text] [Related]
20. Miglitol (BAY m 1099) treatment of diabetic hypothalamic-dietary obese rats improves islet response to glucose.
Axen KV; Li X; Sclafani A
Obes Res; 1999 Jan; 7(1):83-9. PubMed ID: 10023734
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]